pills

Improving Quality of Patient Care While Decreasing Costs in the News This Week

IP Blog | Innovation Partners | November 16, 2017

Front and center in the news this week is both the proposition and the evidence that improving patient care while decreasing costs is possible. Humana offers a study showing how value-based care can improve quality and lower costs at the same time the Trump Administration pushes back against value-based care. Loxo sold Bayer the rights […]

Read Full Post »


Healthcare Marketplace Access News Innovation Partners

CMS Issues Final Rules, UnitedHealth’s Business Moves, and Much More

IP Blog | Innovation Partners | November 12, 2017

This week’s BioBlog takes a look at UnitedHealth’s business moves. While all eyes have been on Amazon, UnitedHealth is, in fact, taking up more market share. In addition to business news, we take a look at the new CMS final rules and their impact, as well as other important industry and business news for healthcare, […]

Read Full Post »


BioBlog-Medicine-Image

Oncology Care, Health Industry Updates and More in the News This Week

IP Blog | Innovation Partners | November 5, 2017

Oncology care takes front and center this week with reports from the CMS on patient care, support for approval of several biosimilar drugs, and a complimentary seminar from the FDA coming up on November 13th. This and more in this week’s Innovation Partners BioBlog. CMS’s Oncology Care Model Has Issues, But Participants Say Care Has […]

Read Full Post »


Researchers at Sloan Kettering working to find ways to help immune checkpoint inhibitors work

Amazon, CVS, Epic and Drugmakers in the News, While Congress Halts Efforts to Repeal and Replace the ACA

IP Blog | Innovation Partners | October 29, 2017

Amazon makes a move to enter the healthcare industry, possibly as a pharmaceutical benefits manager, while Congress shelves plans to repeal and replace the ACA until after the 2018 election. UCLA is under fire for potentially using taxpayer money to create a prostate cancer drug that is being sold at a price tag too high […]

Read Full Post »


prescription pills.

FDA Approves Gilead’s New Treatment for Large B-Cell Lymphoma, Astra and Merck Get Green Light for Fast Review of Lynparza, and More on This Week’s Innovation Partners BioBlog

IP Blog | Innovation Partners | October 22, 2017

This week there’s breakthrough news emerging in the treatment of cancer. The FDA approved Gilead (Kite Pharma’s) gene-therapy treatment for large B-cell lymphoma, offering hope to many patients who didn’t respond well to other treatments. The “cascade of costs” associated with gene therapy, including treatment for side effects, is one factor pushing the price tag […]

Read Full Post »


BioBlog-10-15-image

Cancer Treatment News, Updates on Laws Impacting Healthcare and Insurance Costs and More in This Week’s BioBlog

IP Blog | Innovation Partners | October 15, 2017

In this week’s Innovation Partners BioBlog, cancer is once again in the news, from an increase in obesity and overweight-related cancer diagnosis to drug companies voluntarily lowering chemotherapy drug costs in Africa. President Trump may issue an executive order to undermine portions of the ACA while Iowa is already taking steps in that direction. A […]

Read Full Post »


hepatitis-c-test

New Money Flows into Oncology Sector and More in this Week’s BioBlog

IP Blog | Innovation Partners | October 8, 2017

Oncology treatment and outcomes are front and center this week in the Innovation Partners BioBlog. KSQ Therapeutics is better on CRISPR technology to improve drug development, while Cullinan Oncology takes a funding-based approach to drug development. Other news this week includes the unveiling of a new FDA reporting dashboard, ASCO Advocacy Summit and report from […]

Read Full Post »


The Impact of Medicaid Expansion Under the ACA and the Impact of Changes to 340B, Costs of Services and Pharmaceuticals and More Under Scrutiny.

IP Blog | Innovation Partners | October 1, 2017

This week’s Bio Blog examines the impact of decisions – decisions made by lawmakers, lobbyists, and others as they try to create systems that support healthcare. Medicaid expansion under the ACA is under scrutiny, as are contributions made by pharmaceuticals PACS in 2017. An oncologist penned an insightful essay on the impact of changes to […]

Read Full Post »


BioBlog Weekly image September 24 Innovation Partners

Cost of Prescription Drugs Skyrocketing, Breast Cancer Patients Struggling to Pay for Care, and a New Flurry of Republican-Led Activity to Repeal the ACA in this Week’s Bio Blog

IP Blog | Innovation Partners | September 24, 2017

This week in the Innovation Partners Bio Blog, the attention is on costs – the costs of healthcare premiums, prescription drugs, breast cancer treatments, and more. And while the public’s attention is focused on the rising costs, a Republican-led delegation is once again urging for the repeal of the Affordable Care Act. Last-Ditch Effort By […]

Read Full Post »


Healthcare Marketplace Access News Innovation Partners

Shifting Pharmaceutical Patents to Native American Tribes to Protect Intellectual Property, Shattering the Myth of the Cost of Cancer Drug Development, and More on the Innovation Partners Bio Blog

IP Blog | Dave Melin | September 17, 2017

This week on the Bio Blog, the cost of drugs, especially cancer drugs, is in the spotlight. New evidence indicates that it costs millions, not billions, to produce new cancer medications. California is taking aim at the cost of prescription medicines through the passage of Senate Bill 17 on Monday which will give insurers the […]

Read Full Post »


The Costs of Medications, Updated ESMO Guidelines, and More in This Week’s BioBlog

IP Blog | Dave Melin | September 10, 2017

This week on the Bio Blog, the discussion continues around the cost of medications. U.S. employers seek more narrow insurance benefit designs for employees, and the FDA approved Pfizer’s Mylotarg after a seven-year hiatus. A new app offers data-based symptom tracking for chemotherapy patients, and doctors react to the Trump Administration’s controversial decision to rescind […]

Read Full Post »


BioBlog Weekly oncology

FDA in the News This Week with Changes to Disclosure, Raids and Warnings for Unapproved Stem Cell Treatments

IP Blog | Dave Melin | September 3, 2017

This week on the Bio Blog, the FDA features prominently in the headlines as Commissioner Scott Gottlieb weighs the pros and cons of shorter drug side effect disclosures and leads the charge to protect consumers against unapproved stem cell treatments. A look at this plus the acquisition of Kite Pharma by Gilead and more. What […]

Read Full Post »


IP-logo sq

Pharmaceutical Spotlight: Drug Costs, New Profit/Aging Drugs, Program 340B & More

IP Blog | Dave Melin | August 27, 2017

This week on the BioBlog, we’re taking a closer look at the pharmaceutical industry. Roche is tweaking an aging cancer drug and marketing its replica for MS, demonstrating how profits can be generated from existing medications. Dr. June, the pioneer of immunotherapy, is featured in another article as his treatment developed from research with HIV […]

Read Full Post »


Too Few Patients For Some Drug Trials & Biotech Companies Look at ‘Organs on a Chip’,

IP Blog | Dave Melin | August 21, 2017

This week’s Bio Blog examines several challenges as well as opportunities for biotech and pharmaceutical companies. Although immune therapy and personalized medicine offer many advances in cancer treatment, a lack of suitable patients to test these therapies on may hinder the launch of new drugs. Biotech companies are looking into “organs on a chip”, tissue […]

Read Full Post »


ACA Repeal, Replace or Repairs…is ACA Reform Dead for Now?

IP Blog | Dave Melin | August 13, 2017

This week’s Bioblog focuses on the broader opioid epidemic and concerns over rising incidence of opioid utilization to control cancer pain. President Trump has signified that he will use his bully pulpit to push for new opioid controls and policy changes. Other articles this week include an update and analysis of the Affordable Care Act […]

Read Full Post »


Bio-Blog August 8th, Biopharm news

ACA Repeal Falls Short, Skyrocketing Drug Prices, & A New Digital Health Innovation Action Plan From The FDA

IP Blog | Dave Melin | August 6, 2017

This week’s BioBlog explores many topics related to the biopharmaceutical industry and the Affordable Care Act. Articles on 340B program, the approval of Celgene and Agios’ enasidenib (AG-221), the rising costs of drugs, and other issues directly impacting healthcare throughout America demonstrate the continued need for reform and innovation in the broader healthcare industry. ASCO […]

Read Full Post »


BioBlog Weekly oncology

Obamacare Repeal Failure and Cancer Research Developments

IP Blog | Dave Melin | July 30, 2017

In this week’s BioBlog we look at the failure of the senate to pass a healthcare bill to repeal Obamacare and what it means for insurers and the market. We also look at new developments in cancer research in cancer gene mapping and stem cell therapy. Repeal is Dead (for Now). But Will Obamacare Survive? A […]

Read Full Post »


BioBlog Weekly oncology

New Drugs and Treatments for Leukemia, Alzheimer’s, and Hemophilia

IP Blog | Dave Melin | July 23, 2017

In this week’s BioBlog we learn about new drugs and treatments for leukemia, Alzheimer’s disease, and hemophilia. We also look at a new way the Mayo Clinic is using artificial intelligence to look for potential new drug application, along with Alaska receiving approval for a plan to help stabilize the ACA marketplace in the state. […]

Read Full Post »


BioBlog Weekly oncology

Cancer Drug Research and Pricing and More

IP Blog | Dave Melin | July 16, 2017

In this week’s BioBlog we look at recent happenings in the development and research of cancer drugs, cancer drug price increases, a push by democrats for single-payer healthcare, new Alzheimer disease research, and the ongoing opioid prescription crisis in the US. Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds […]

Read Full Post »


BioBlog Weekly oncology

Exciting New Research and Treatments for Leukemia

IP Blog | Dave Melin | July 9, 2017

In this week’s BioBlog we look into several new studies for Acute Myeloid Leukemia, along with promising new drugs to help treat and reduce relapse occurrence in AML patients. Stem-Cell Researchers Solve Mystery of Relapse in Acute Myeloid Leukemia Scientists have identified a specific type of stem-cell that is present at the time of diagnosis […]

Read Full Post »


BioBlog Weekly oncology

Drug Pricing, MACRA Exemptions, Healthcare Exchange Profitability, and Artificial Intelligence in Healthcare

IP Blog | Dave Melin | July 2, 2017

In this week’s BioBlog we look at the latest developments in the ongoing drug pricing battle, another group of providers receiving exemption from the MACRA requirements, and look into the future of using artificial intelligence in healthcare. Draft Order on Drug Prices Proposes Easing Regulations The New York Times reports that a draft of an […]

Read Full Post »


BioBlog Weekly oncology

In’s and Out’s of the Senate Healthcare Bill

IP Blog | Dave Melin | June 25, 2017

This week’s BioBlog explores various aspects of the Senate’s Healthcare Bill. Senate Republicans Reveal Long-Awaited Affordable Care Act Repeal Bill In this article, NPR highlights the major changes that would occur if the newly released senate healthcare bill passes. CHART: Who Wins, Who Loses With Senate Health Care Bill The chart in this article highlights […]

Read Full Post »


BioBlog Weekly oncology

New Investments, Sharpless Appointment, New Cancer Treatment Discoveries

IP Blog | Dave Melin | June 18, 2017

In this week’s BioBlog we learn more about Google’s recent investments in the pharmaceutical and medical industry, Cigna’s continued support of Omada Health, Trump’s recent appointing of Sharpless, and potential new treatments for cancer. Google Is Ramping Up Pharma Activity Google continues to expand their investments in the pharmaceutical field this year, continuing on recent indications […]

Read Full Post »


BioBlog Weekly oncology

BioBlog ASCO Recap Edition

IP Blog | Dave Melin | June 7, 2017

This special edition of the BioBlog outlines the issues, happenings and information relevant to this year’s ASCO Annual Meeting held June 1 – 5 in Chicago. Cancer Drug Prices Could Double or Triple Thanks to This Popular but Unproven Drug Trend This online article from MarketWatch outlines the “safety concerns and issues of price hang above […]

Read Full Post »


BioBlog Weekly oncology

Cancer Research Funding, CancerLinQ, Superbug Treatment, ADHD Drugs, Big Pharma, Medicaid Growth, and the Opioid Crisis

IP Blog | Dave Melin | June 5, 2017

In this week’s BioBlog we look at recent developments across the healthcare field, including cancer research funding and data tracking of cancer treatments, a revamped antibiotic to combat superbugs, ADHD medication, Big Pharma, Medicaid enrollment, and the opioid crisis. As Government-Funded Cancer Research Sags, Scientists Fear U.S. Is ‘Losing Its Edge’ Looking ahead to significant […]

Read Full Post »


BioBlog Weekly oncology

Advancements in the Treatment and Prevention of Various Types of Cancer

IP Blog | Dave Melin | May 29, 2017

In this week’s BioBlog, we look at recent advancements in cancer drugs, treatments, and ways to cut risks of getting cancer. Brigatinib First Drug to Offer Over 1-Year Control of ALK-Positive Lung Cancer Post-Crizotinib Promising new findings show that the drug, Brigatinib, has a 54 percent response rate in cancers that didn’t respond to Crizotinib. […]

Read Full Post »


BioBlog Weekly oncology

Drug Pricing, MACRA Requirement, and Alternative Payment Models

IP Blog | Dave Melin | May 21, 2017

In this week’s BioBlog we read about recent developments in the ongoing fight to lower drug prices, ASCO’s new payment model alternative, and more physicians being excluded from the MACRA requirements. The White House Budget Director Dropped a Hint About How Trump Could Bring Drug Prices Down Mick Mulvaney suggested that it is possible that […]

Read Full Post »


BioBlog Weekly oncology

Obamacare, Trumpcare, Uninsured with Cancer, Research Efforts

IP Blog | Dave Melin | May 14, 2017

In this week’s BioBlog we look at the fallout from the uncertain future of Obamacare, Trumpcare’s position on pre-existing conditions, the challenge of diagnosing cancer early in patients without insurance, and new research to try and detect cancer earlier. Obamacare Premiums Rise as Insurers Fret Over Law’s Shaky Future With the uncertain future of Obamacare […]

Read Full Post »


BioBlog Weekly oncology

Trumpcare, Value Frameworks, GA Firefighter Cancer Bill Signed

IP Blog | Dave Melin | May 8, 2017

In this week’s BioBlog we look at the AHCA bill contents as it was passed by the House, the need to revamp value frameworks to make them a useful tool, as well as an exciting new bill passed in Georgia to get firefighters covered for various types of cancer. House Gives Green Light to Amended […]

Read Full Post »


BioBlog Weekly oncology

Drug Costs, Federal Funding, New Partnerships, and Supreme Court Hearings

IP Blog | Dave Melin | April 30, 2017

In this week’s BioBlog we explore the ending of a major contract between Express Scripts and Anthem, the continued battle over drug costs, an Upcoming meeting between the Trump administration and drug companies, a new partnership between Walgreens and Prime, and a highly anticipated hearing in the Supreme Court. A Huge Pharma Middleman Just Lost […]

Read Full Post »